CareDx (NASDAQ:CDNA) Stock Rating Lowered by Craig Hallum

CareDx (NASDAQ:CDNA – Get Rating) was downgraded by Craig Hallum from a “buy” rating to a “hold” rating in a report released on Friday, The Fly reports. They presently have a $9.00 price target on the stock, down from their previous price target of $26.00. Craig Hallum’s price objective would indicate a potential upside of 0.33% from the company’s current price.

Other equities analysts also recently issued research reports about the company. BTIG Research cut their target price on CareDx from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, February 28th. The Goldman Sachs Group cut their target price on CareDx from $29.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, February 28th. StockNews.com downgraded CareDx from a “hold” rating to a “sell” rating in a research report on Tuesday, February 28th. Stephens reaffirmed an “overweight” rating and set a $19.00 price target on shares of CareDx in a report on Tuesday, February 28th. Finally, Raymond James cut CareDx from a “strong-buy” rating to a “market perform” rating and set a $24.00 price target for the company. in a report on Friday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, CareDx currently has an average rating of “Hold” and a consensus price target of $20.40.

CareDx Price Performance

CareDx stock opened at $8.97 on Friday. The company has a market capitalization of $481.42 million, a PE ratio of -6.23 and a beta of 1.03. CareDx has a one year low of $8.10 and a one year high of $41.50. The business has a 50 day simple moving average of $14.00 and a 200 day simple moving average of $15.53.

Insider Activity

In other news, insider Reginald Seeto sold 11,094 shares of CareDx stock in a transaction on Thursday, February 9th. The stock was sold at an average price of $16.13, for a total value of $178,946.22. Following the completion of the sale, the insider now directly owns 551,940 shares of the company’s stock, valued at approximately $8,902,792.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Peter Maag sold 5,000 shares of the firm’s stock in a transaction on Thursday, February 2nd. The stock was sold at an average price of $17.17, for a total value of $85,850.00. Following the transaction, the director now directly owns 298,737 shares in the company, valued at approximately $5,129,314.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Reginald Seeto sold 11,094 shares of the firm’s stock in a transaction on Thursday, February 9th. The stock was sold at an average price of $16.13, for a total value of $178,946.22. Following the completion of the transaction, the insider now owns 551,940 shares in the company, valued at $8,902,792.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,069 shares of company stock valued at $447,903. Company insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rockefeller Capital Management L.P. boosted its position in shares of CareDx by 272.4% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 4,108 shares of the company’s stock worth $69,000 after purchasing an additional 3,005 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of CareDx by 27.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,540 shares of the company’s stock worth $109,000 after purchasing an additional 2,029 shares during the last quarter. Lazard Asset Management LLC lifted its holdings in CareDx by 64.0% during the second quarter. Lazard Asset Management LLC now owns 5,290 shares of the company’s stock worth $113,000 after acquiring an additional 2,065 shares in the last quarter. Alpine Global Management LLC bought a new position in CareDx during the fourth quarter worth about $121,000. Finally, Shell Asset Management Co. lifted its holdings in CareDx by 152.9% during the second quarter. Shell Asset Management Co. now owns 5,953 shares of the company’s stock worth $128,000 after acquiring an additional 3,599 shares in the last quarter.

CareDx Company Profile

(Get Rating)

CareDx, Inc operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.